Genenta Science Spa Stock Price, News & Analysis

Genenta Science (NASDAQ: GNTA) has filed its annual report on Form 20-F for the fiscal year ending December 31, 2021, with the SEC on May 2, 2022. The report is available on the company's investor relations website and the SEC's website. Genenta is specializing in hematopoietic stem cell gene therapy, particularly its Temferon™ treatment for Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter. The company emphasizes that forward-looking statements in the report are subject to risks and uncertainties, including those related to ongoing clinical trials.

Genenta Science (NASDAQ: GNTA) has announced an escalation in its ongoing Phase 1/2a clinical trial of Temferon™ for glioblastoma multiforme patients with an unmethylated MGMT gene promoter. The trial has dosed its first patient in cohort 6 at 3.0 x 10⁶ cells per kilogram, a 50% increase from the previous maximum dose, after no dose-limiting toxicities were observed. The company aims to complete patient enrollment in cohorts 6 and 7 by mid-2023. CEO Pierluigi Paracchi noted the significance of this step in confirming Temferon's mechanism and therapeutic potential.

Genenta Science (NASDAQ: GNTA) announced preliminary findings from its Phase 1/2a study of Temferon™ for glioblastoma multiforme (uMGMT-GBM). The results show Temferon's potential to modulate the tumor microenvironment, with a positive safety profile. Fifteen patients received the treatment, showing successful engraftment and no drug-limiting toxicities. Preliminary signals of biological activity were observed, including gene-marked cells in tumors of patients who underwent surgery. The findings will be presented at the ASGCT meeting on May 19, 2022.

Genenta Science (NASDAQ: GNTA) has announced the appointment of Mark A. Sirgo, PharmD, as the new Chair, succeeding Stephen Squinto, who is stepping down to pursue a new opportunity. Dr. Sirgo brings over 35 years of pharmaceutical experience, including a successful tenure as CEO of Biodelivery Sciences, where he raised over $600 million and increased the market cap from $10 million to nearly $1 billion. His appointment is subject to shareholder approval at the next AGM. The company is advancing its proprietary stem cell gene therapy Temferon™ in clinical trials for solid tumor cancers.

Genenta Science (NASDAQ: GNTA) announced a webinar titled "Expert Perspectives: Immuno Gene & Cell Therapy for the Treatment of Solid Tumors," scheduled for April 28, 2022, at 8:00 AM EDT. Esteemed speakers include neuro-oncologist David Reardon from Harvard Medical School and gene therapy pioneer Luigi Naldini. The discussion will focus on Genenta's Temferon™, an innovative gene therapy aimed at treating glioblastoma and solid tumors. A Q&A session will follow. Registration is available via Genenta's news release.

Genenta Science (NASDAQ: GNTA) announced that it will present clinical data at the 2022 American Association for Cancer Research (AACR) meeting regarding its Temferon™ treatment for glioblastoma multiforme patients with unmethylated MGMT gene promoter (uMGMT-GBM). Data from 15 patients suggest successful engraftment of gene-modified cells and maintained levels for up to 18 months post-treatment.

Safety continues to be a focus, with manageable adverse events linked primarily to chemotherapy. The presentation is scheduled for April 8-13, 2022, in New Orleans.

Genenta Science (NASDAQ: GNTA) announced its participation in several upcoming investor conferences. The events include the 34th Annual ROTH Conference on March 13-15, Maxim Group LLC 2022 Virtual Growth Conference on March 28, and the HC Wainwright Gene Therapy and Gene Editing Conference on March 30. Management, including CEO Pierluigi Paracchi and CMO Carlo Russo, will engage in fireside chats and one-on-one meetings with investors. Genenta is focused on developing Temferon™, a novel gene therapy targeting solid tumors.

On December 17, 2021, Genenta Science (Nasdaq: GNTA) announced the completion of its upsized initial public offering, raising approximately $36 million by selling 2.4 million ADSs at $11.50 each, along with 720,114 ordinary shares to existing shareholders. The offering began trading on December 15, 2021. Roth Capital Partners and Maxim Group are involved in managing the offering. Additionally, the underwriters have a 30-day option to purchase an additional 360,000 ADSs, potentially increasing the total proceeds to around $40 million.

Genenta Science announced the pricing of its upsized initial public offering (IPO) of 2.4 million American Depositary Shares (ADSs), each priced at $11.50 per share. This offering is expected to generate approximately $36 million in gross proceeds, potentially rising to $40 million if underwriters exercise their purchase option. Trading under the ticker symbol GNTA on the Nasdaq begins on December 15, 2021, with the offering closing anticipated by December 17, 2021, pending customary conditions.